Explore

Trendline Trendline
Moderna's Norovirus Vaccine Trial Faces Setback, Extends into Fourth Season

Moderna's Norovirus Vaccine Trial Faces Setback, Extends into Fourth Season

Moderna's Norovirus Vaccine Trial Faces Setback, Extends into Fourth Season
Trendline Trendline
FDA Nears Decision on Moderna's mRNA Flu Vaccine Amid Industry Concerns

FDA Nears Decision on Moderna's mRNA Flu Vaccine Amid Industry Concerns

FDA Nears Decision on Moderna's mRNA Flu Vaccine Amid Industry Concerns
Trendline Trendline
Moderna Reports Q2 2026 Revenue of $145M Amid $782M Net Loss, Projects Revenue Growth

Moderna Reports Q2 2026 Revenue of $145M Amid $782M Net Loss, Projects Revenue Growth

Moderna Reports Q2 2026 Revenue of $145M Amid $782M Net Loss, Projects Revenue Growth
Trendline Trendline
Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop
Trendline Trendline
Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock

Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock

Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock
Trendline Trendline
Viking Therapeutics Reports Strong Financial Position and Advances Obesity Treatment Trials

Viking Therapeutics Reports Strong Financial Position and Advances Obesity Treatment Trials

Viking Therapeutics Reports Strong Financial Position and Advances Obesity Treatment Trials
Trendline Trendline
Orano Med Reports Progress in Nuclear Medicine and Business Outlook

Orano Med Reports Progress in Nuclear Medicine and Business Outlook

Orano Med Reports Progress in Nuclear Medicine and Business Outlook
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint
Trendline Trendline
FDA Advisory Committee Supports Replimune's Melanoma Drug Amid Data Concerns

FDA Advisory Committee Supports Replimune's Melanoma Drug Amid Data Concerns

FDA Advisory Committee Supports Replimune's Melanoma Drug Amid Data Concerns
Trendline Trendline
Johnson Johnson Receives FDA Clearance for Surgical Robot Amidst Revenue Growth

Johnson Johnson Receives FDA Clearance for Surgical Robot Amidst Revenue Growth

Johnson Johnson Receives FDA Clearance for Surgical Robot Amidst Revenue Growth
Trendline Trendline
AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted
Trendline Trendline
Boston Scientific Reports 7.5% Revenue Growth in Q2 2026 Amid Dynamic Market Conditions

Boston Scientific Reports 7.5% Revenue Growth in Q2 2026 Amid Dynamic Market Conditions

Boston Scientific Reports 7.5% Revenue Growth in Q2 2026 Amid Dynamic Market Conditions